Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 519 |
| Active Pipeline (Recruiting Now) | 344 (201) |
| Completed vs Stopped Early | 38 / 137 (26.4%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| MD Anderson Cancer Center | Houston, TX | 481 |
| Dana-Farber Cancer Institute | Boston, MA | 9 |
| Memorial Sloan Kettering Cancer Center | New York, NY | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03583710 | Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for MD Anderson Cancer Center across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the MD Anderson Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.